🇺🇸 FDA
Patent

US 11578081

Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof

granted A61KA61K31/519A61P

Quick answer

US patent 11578081 (Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof) held by Medshine Discovery Inc. expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/519, A61P, A61P3/04, A61P3/06